Comparative Efficacy of High-Dose Daptomycin Monotherapy versus Combination Therapy for Daptomycin-Resistant Enterococcus faecium Endocarditis in a Rat Model

高剂量达托霉素单药治疗与联合治疗在达托霉素耐药粪肠球菌心内膜炎大鼠模型中的疗效比较

阅读:1

Abstract

BACKGROUND: Infections caused by daptomycin-resistant and vancomycin-resistant Enterococcus faecium (DRE) are a critical clinical challenge with limited therapeutic options. This study aimed to compare the efficacy of high-dose daptomycin monotherapy against combination therapies in a rat model of DRE infective endocarditis (IE). METHODS: A clinical DRE isolate (daptomycin MIC, 8 mg/L) was used to establish IE in Wistar rats. After 48  h, the animals were randomized to three-day regimens: saline control, daptomycin 90 mg/kg/day s.c. (D90), daptomycin 125 mg/kg/day s.c. (D125), D90 plus fosfomycin 500 mg/kg/day i.p. (D90F), or D90 plus ceftaroline 40 mg/kg q8 h i.m. (D90C). Efficacy was evaluated by quantifying colony-forming units (CFU) in excised cardiac vegetation. RESULTS: A strong correlation was observed between higher daptomycin exposure (Cmax/MIC and AUC(0) (-2) (4)/MIC) and lower vegetation bacterial density (p < 0.01 for both). High-dose daptomycin monotherapy (D125) was the most effective regimen, resulting in the lowest mean vegetation bacterial load (4.75 log(1) (0) CFU/g). This was significantly lower than the bacterial load in the D90F group (5.62 log(1) (0) CFU/g; p = 0.02) and showed a trend towards superiority over the D90C group (5.87 log(1) (0) CFU/g; p = 0.05). CONCLUSION: In this severe DRE infection model, escalating the daptomycin dose was more effective in clearing bacteria from the cardiac vegetation than combining a standard high dose with a synergistic agent. These findings suggest that higher daptomycin exposure may be a viable strategy for managing DRE infections, pending clinical validation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。